Both Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies are produced during the primary immune response. As the body’s largest antibody, IgM is the first antibody to appear in response to an initial exposure to antigens. IgM provides the first line of defence during viral infections, followed by the generation of adaptive, high affinity Immunoglobulin G (IgG) responses for long-term immunity and immunological memory. IgG is usually detectable about 7 days after the IgM appears.
We urge world to 'test, test, test' for COVID-19
10 MINUTES
Covid-19 Rapid IgG/IgM combined Antibody assay Pre screening test Kit
Kit Model # ERCSSO5310
No lab visits, no doctors
Just one finger prick of blood
Order Now
Screening is Critical for Community Pulse.
"We urge world to 'test, test, test' for COVID-19"
Current method
Our Method
Pre Screening
Benefits
of pre-screening
Exponentially faster
No Queues, No Wait time for results
Exponentially more cost effective
Early Detection & Elimination
Effort less, and accessible to everyone
nationwide, instantly
Viable precautionary step
Detection Period
10 MINUTES
Easy operation without requirement of any
Doctor or Professional Nurse
No special equipment storage and transportation
conditions required
Works with whole blood, serum, and plasma
Tests for 2 antibodies IgM and IgG
simultaneously
Instant Field screening
100% Accurate
in detecting Corona Virus antibodies.
99.31% Accurate in ruling them out.
Current Distribution
Worldwide approximate
-
Italy
-
Spain
-
Germany
-
UK
-
Czech
-
Swiss
-
Korea
-
China
-
Lebanon
-
Japan
-
India
-
Netherlands
-
UAE
-
Indonesia
-
South America
PLUS 27 more countries
and growing rapidly daily
CE European Approval Certified
ICMR Recommended
Discover if you are exposed in 10 minutes?
Effective Use
- Hospitals
- Corporate CSR
- Physicians Clinics
- Community Doctors
- Doctors Without Borders
- Practicing Doctors
- General Practitioners
- Nurses and Professionals
- Ayurvedic and Homeopathic Doctors
- Alternative Medicine
- Integrative Medicine Practitioners
- Emergency Response Teams
- Governmental Institutions
- Clinical Researchers
Detection
Process
It is widely accepted that IgM provides the first line of defence during viral infections, followed by the generation of adaptive, high affinity IgG responses for long term immunity and immunological memory. Therefore testing of COVID-19 IgM and IgG antibodies is an effective method for the rapid screening of COVID-19 infection. Furthermore, detection of COVID-19 IgM antibodies tends to indicate a recent exposure to COVID-19, whereas detection of COVID-19 IgG antibodies indicates a later stage of infection. Thus, this combined antibody test could also provide information on the stage of infection.
Fluorescence PCR | CLIA | "Colloidal Gold Method (our method)" | |
---|---|---|---|
Detection substance | Nucleic acid | Antibody | Antibody |
Type of sample | "Nasopharyngeal swabs, sputum, alveolar lavage fluid " | Serum/ Plasma | Serum/ Plasma/ Whole blood |
Time to get result | 2 hrs | 20 mins | Fastest 10 minutes |
Instrument needed or not | Yes | Yes, i 3000, i 1000 | Not needed |
Laboratory requirement | High | Relatively high | Average |
Product Usage | Confirming diagnosis | Nucleic acid negative sample reviewing or high-volume sample detection | Nucleic acid negative sample reviewing or basic hospital sample testing |
Colloidal Gold Method: The 2019-nCOV IgG/IgM Rapid Test Device using this Method is a rapid chromatographic immunoassay for the qualitative detection of IgG & IgM antibody of Coronavirus in human whole blood, serum, or plasma |
RT-PCR Vs Covid19 IgG/IgM Rapid Test
Comparative Test Summary
The Covid-19 IgG/IgM rapid test and the SARS-CoV-2 RT-PCR test were detected simultaneously and the Sensitivity (positive coincidence rate), Specificity (negative coincidence rate), and Accuracy (total coincidence rate) were calculated:
In this clinical trial, total, 547 test samples (258 positive and 289 negative) were included for the unit and all test samples included are tested. Statistics on test results and those of the product tested at >/= 15 days after onset of symptoms are as follows:
Antibody | Specificity | Sensitivity |
---|---|---|
IgG | 99.31% | 100% |
IgM | 97.58% | 92% |
Cross-reactivity
Cross-reactivity of Covid-19 Rapid IgM/IgG Combined Antibody Assay Pre-Screening Kit was evaluated with Positive serum specimens of different respiratory diseases.
No false positivity or false negativity was found with the following:
HBsAg | Influenza A |
FLU-A | Influenza B |
FLU-B | TP |
HCV | Respiratory syncytial virus (RSV) |
HIV-1 | RF |
HIV-2 | Chlamydia pneumonia (CP) |
Adenovirus | Mycoplasma pneumonia (MP) |
Parainfluenza virus 1-4 |
Potentially Interfering Substances
The following substances have been tested using Covid-19 Rapid IgM/IgG Combined Antibody Assay Pre-Screening Test Kit to evaluate potential endogenous interference. The IgM positive, IgG positive and negative samples were used to dilute the interferents to following concentrations.
Interfering substances | Concentration |
---|---|
Ascorbic acid | 0.2mg/ml |
Hemoglobin | 10mg/ml |
Bilirubin | 0.6mg/ml |
Oxalic acid | 1mg/ml |
Human serum albumin | 20mg/ml |
Triglyceride | 50mg/ml |
Both Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies are produced during the primary immune response. As the body’s largest antibody, IgM is the first antibody to appear in response to an initial exposure to antigens. IgM provides the first line of defence during viral infections, followed by the generation of adaptive, high affinity Immunoglobulin G (IgG) responses for long-term immunity and immunological memory. IgG is usually detectable about 7 days after the IgM appears.
2. In the early onset of fever, anti-COVID-19 IgM concentrations may be below detectable levels.
3. The continued presence or absence of antibodies cannot be used to determine the success or failure of therapy.
4. Results from immunosuppressed patients should be interpreted with caution.
5. As with all diagnostic tests, all results must be interpreted together with other clinical information available to the physician.
6. If the test result is negative and clinical symptoms persist additional testing using other clinical methods is recommended. A negative result does not at any time preclude the possibility of COVID-19 infection.
Once scientists know who has had the virus, they can find out how sick it makes most people. And they can study what happens if people who've had it come into contact with it again. Along with other scientific information, this can help researchers understand who might be immune to the virus.
The hope is that people with antibodies to COVID-19 can safely get back to work, and normal life, quicker.
These tests may also help with an experimental treatment for COVID-19 called convalescent plasma. Plasma is the liquid part of your blood.
Researchers are studying how antibodies in plasma donated by people who’ve recovered from COVID-19 might help those who are ill with the virus. One theory is that this plasma may help sick people get better faster. But more research is needed.
You can volunteer to donate plasma through the National COVID-19 Convalescent Plasma Project. Or ask your local blood donation center for information.
Antibody Testing is a preventative step. One Test. Ten Minutes.
In Connivance of your clinic.
Try Today.
Compare with PCR Results and see for yourself.